Indian Journal of Clinical and Experimental Ophthalmology

Print ISSN: 2395-1443

Online ISSN: 2395-1451


Indian Journal of Clinical and Experimental Ophthalmology (IJCEO) is open access, a peer-reviewed medical journal, published quarterly, online, and in print, by the  Innovative Education and Scientific Research Foundation (IESRF) since 2015. To fulfill our aim of rapid dissemination of knowledge, we publish articles ‘Ahead of Print’ on acceptance. In addition, the journal allows free more...

  • Article highlights
  • Article tables
  • Article images

Article statistics

Viewed: 80

PDF Downloaded: 75

Babu M N, Prashanth C N, and Natesh: Diabetic macular edema shows a positive response to Aflibercept after previous unresponsive intravitreal Anti-VEGF and steroid therapy


Diabetic macular edema (DME) is the common cause of visual impairment in patients with diabetic mellitus.1 The common microvascular complication of diabetes is retinopathy; micro aneurysm, blood retinal barrier dysfunction, and capillary drop out are important contributors of DME.2 Vascular endothelial growth factor (VEGF) is an important mediator of abnormal vascular permeability in DME.3, 4

Currently anti VEGF (intravitreal aflibercept, ranibizumab, and off label use of bevacizumab) and corticosteroids5, 6, 7, 8, 9 are used for treatment for DME. Aflibercept is a recombinant fusion protein consisting of portion of human VEGFR-1 and VEGFR-2 extracellular domains fused to the Fc portion of human IgG1- iso osmotic solution for intravitreal administration.

Figure 0

Aflibercept has a high affinity for all isoforms of VEGF-A as well as PIGF.10 VEGF is typically present in dimeric form, with receptor binding sites located at each pole of the dimer. The molecular structure of aflibercept was designed for tight binding to both end of multiple VEGF subtypes.11 The results is exponentially greater affinity for VEGF-A. One study showed that the binding affinity of aflibercept was 140 times that of ranibizumab.12 In addition Eylea has the unique property of being able to bind to VEGF-B as well as PIFG.10 Aflibercept have longer half-life compared with ranibizumab.13

In our study we included DME unresponsive to prior anti VEGF therapy and intravitreal steroid for treatment with single injection of intravitreal aflibercept to report the post injection effect.

Materials and Methods

Our study is prospective, consecutive, non-randomized case series.10 eyes of 8 patients with DME unresponsive to prior anti VEGF therapy and intravitreal steroids were included. We excluded newly diagnosed central macular edema and Non central macular edema.

Informed consent was procured prior to recruitment in a consecutive manner. Each patient underwent detail eye examination include best corrected visual acuity (BCVA), anterior segment examination, intraocular pressure (IOP) and fundus examination. OCT (Spectral domain – primus Zeiss) scan was done each visit. Each patient received one intravitreal aflibercept injection. Central foveal thickness (CFT) was measured at presentation, at 15 days and 45 days after intravitreal aflibercept injection. Follow up done for 6 months, repeat intravitreal injection done for recurrent macular edema.


A total of 10 eyes of 8 patients (6 unilateral, 2 bilateral) were reviewed. There were 7 males (87.5%) patient and 1 female (12.5%).

Mean BCVA at presentation was 0.85 log MAR, and that improved to after 15 days and 45 days of intravitreal aflibercept was 0.65 log MAR and 0.52 log MAR.

Figure 1

Mean Central macular edema at presentation was 662.5 μm (380-905μm), after 15 days was 403μm (185-705 μm) and after 45 days was 261.25μm (120-507μm).

Figure 2

Case 1

A 38 years old male had non resolving ME in both eyes after 3 doses of intravitreal bevacizumab injections given at 6 weekly intervals. He received Aflibercept injection in both eyes. His vision in Right eye (RE) was 6/36 and left eye(LE) was 6/60 which improved to 6/6 in RE and 6/9 in LE at 45 days of intravitreal aflibercept injection.

Figure 3

RE fundus shows multiple hard exudate with ME and superficial haemorrhages, OCT shows multiple cystoid changes with SRF fluid with good IS/OS junction and few hard exudate far away from fovea.

After 45 days

Figure 4

RE fundus shows multiple resolving hard exudate with reduced ME and few cotton wool spots, OCT shows normal foveal contour with few hyper reflex dots in foveal region with good IS/OS junction.

Figure 5

LE fundus shows multiple hard exudate with ME and superficial haemorrhage, OCT shows multiple cystoid changes with SRF fluid with good IS/OS junction and few hard exudate far away from fovea.

After 45 days

Figure 6

LE fundus shows multiple resolving hard exudate with reduced ME and few cotton wool spots, OCT shows mild SRF fluid with good IS/OS junction and few hard exudate far away from fovea with reduced ME.

Case 2

A male aged 55 years had non resolving ME in RE in spite of having received 3 doses of intravitreal bevacizumab, 5 dose of intravitreal Ranizumab and 1 dose of intravitreal Ozurdex over 2 years period. His vision in RE was 6/36 improved to 6/9 after 45 days of intravitreal Aflibercept injection. RE shows multiple hard exudate with ME, OCT shows central ME with few areas IS/OS junction disruption and few hyper reflex dots and ERM far away from fovea (Figure 8). After Aflibercept injection RE OCT picture shows normal fovea contour with few hyper reflex dots (Figure 8).

Figure 7

Case 3

A male 78 years old had non resolving ME in RE in spite of received 6 dose of intravitreal bevacizumab, 1 dose of ozurdex and focal laser over 18 months period. His vision in RE was 6/60 and improved to 6/24 after aflibercept injection. RE fundus shows few hard exudate with macular edema, OCT shows central cystoid macular edema with few hyper reflex dots (Figure 3a). After aflibercept injection RE OCT picture shows cystoid ME with mild disruption of IS/OS junction (Figure 9).

Figure 8

In our study shows out of 10 eyes, complete resolution of macular edema seen in 7 eyes (70%), significant resolution of macular edema seen in 1 case (10%) and mild resolution of macular edema in 2 case (20%).


DME is the common cause of visual impairment in patients of retinopathy with diabetic mellitus. VEGF is an important mediator of abnormal vascular permeability in DME.3, 4, 14 Aflibercept is the newer drug and it appears to have theoretical advantage of :(a) had greater affinity to VEGF-A10 (b) it binds to growth factor PGF 1 and VEGF-B10 and (c) the vitreous half-life is 7.3 days.13

Our definition of unresponsive is arbitrary but consistent with other studies; persistent or increasing sub or intraretinal fluid after 3 or more consecutive monthly injections.15, 16

In our study we noticed significant reduction of macular edema with improvement in vision in majority of the patient after switch to intravitreal aflibercept injection. Patient who have long standing disease have more chance to develop receptor resistance to the anti VEGF and steroid drug. The reasons for a response to a newer drug after being refractory or unresponsive to a intravitreal injection may be many. Tachphylaxis may be one. There is also a possibility of certain set of patients being responsive to one drug over the other. Receptors for VEGFs may vary from patient to patient. In our case series we noticed significant reduction of macular edema in 80% of eyes whereas 20% eyes had only mild resolution. Mean BCVA improved from 0.85 log MAR to 0.52 log MAR at 6 weeks. Mean Central macular edema was reduced from 662.5 μm to 261.25μm at 6 weeks. The reason for mild reduction in 20% of patients may be many and needs a larger study looking for the concentration of VEGF levels in the vitreous cavity and invitro studies of response to a particular molecule.

Filipe Mira et al17 is retrospective review of DME unresponsive to previous anti VEGF switched to aflibercept with 3 months follow up showed Central macular edema reduced from 501.47μm ±150.51μm to 367.97μm ±124.61μm at 3 months and log MAR BCVA improved from 0.76±0.36 to 0.65+-0.33 at 3 months comparably to our case series.


Management of unresponsive DME is challenging for retina specialist. We require treatment armamentarium to manage unresponsive DME apart from improving the systemic health. Aflibercept can be an option we can try for these patients. Aflibercept had a significant anatomical and functional improvement in DME patients in our study.

Timing of switching the therapeutic agents, choosing an ideal molecule and biomarkers to suggest the same is the need from future studies.

Source of Funding


Conflict of Interest




R Klein BEK Klein SE Moss Visual Impairment in DiabetesOphthalmology19849111910.1016/s0161-6420(84)34337-8


DA Antonetti R Klein TW Gardner Diabetic RetinopathyN Engl J Med2012366131227910.1056/nejmra1005073


LP Aiello RL Avery PG Arrigg BA Keyt HD Jampel ST Shah Vascular Endothelial Growth Factor in Ocular Fluid of Patients with Diabetic Retinopathy and Other Retinal DisordersN Engl J Med1994331221480710.1056/nejm199412013312203


LA Hollinger EB Wolpert DA Antonetti AJ Barber TW Gardner Vascular Endothelial Growth Factor Induces Rapid Phosphorylation of Tight Junction Proteins Occludin and Zonula Occluden 1J Biol Chem19992743323463710.1074/jbc.274.33.23463


QD Nguyen DM Brown DM Marcus RISE AND RIDE Research Group.Ranibizumab for diabetic macular edema:results from phase 3 randomized trials : RISE AND RIDEOphthalmology20121194789801


DM Brown U Schmidt-Erfurt DV Do FG Holz DS Boyer E Midena Intravitreal aflibercept for diabetic macular edema :100 week result from VISTA and VIVID STUDIESOphthalmology201512210204452


R Rajendra S Fraser-Bell A Kaines A 2 year prospective randomized controlled trial of intravitreal bevacizumab or laser therapy (BOLT)in the management of diabetic macular edema:24 month data:report 3Arch ophthalmology201213023128


TA Ciulla A Harris N McIntyre C Jonescu-Cuypers Treatment of diabetic macular edema with sustained-release glucocorticoids: intravitreal triamcinolone acetonide, dexamethasone implant, and fluocinolone acetonide implantExp Opin Pharmacother2014157953910.1517/14656566.2014.896899


RP Maurya Dabetic macular edema: An overviewIndian J Clin Exp Ophthalmol2019511210.18231/2395-1451.2019.0026


N Papadopoulos J Martin Q Ruan A Rafique MP Rosconi Binding and neutralization of vascular endothelial growth factor (VEGF) and related ligands by VEGF Trap, ranibizumab and bevacizumabAngiogenesis201215217185


AK Olsson A Dimberg J Kreuger L Claesson-Welsh VEGF receptor signalling ? in control of vascular functionNat Rev Mol Cell Biol2006753597110.1038/nrm1911


MW Stewart PJ Rosenfeld FM Penha F Wang Z Yahoshua PF Bueno-Lopez Pharmacokinetic rationale for dosing every 2 weeks versus 4 weeks with intravitreal ranibizumab, bevacizumab, and aflibercept (vascular endothelial growth factor Trap-eye)Retina201232343457


MW Stewart PJ Rosenfeld Predicted biological activity of intravitreal VEGF TrapBr J Ophthalmol2008925667810.1136/bjo.2007.134874


S K Gupta I Yadav S Deshmukh R P Maurya V P Singh Predictors of visual response to Intravitreal Bevacizumab for treatment of Diabetic Macular EdemaIndian Journal of Clinical and Experimental Ophthalmology2015113540


J Pinheiro-Costa JM Costa JN Beato P Freitas-da-Costa E Brandão MS Falcão Switch to Aflibercept in the Treatment of Neovascular AMD: One-Year Results in Clinical PracticeOphthalmologica20152333-41556110.1159/000381221


HF Riederle M Becker N Graf S Michels Effect of aflibercept in insufficient responders to prior anti-VEGF therapy in neovascular AMDGraefe's Archi Clin Exp Ophthalmol2014252111705910.1007/s00417-014-2589-3


F Mira M Paulo F Henriques J Figueira Switch to Aflibercept in Diabetic Macular Edema Patients Unresponsive to Previous Anti-VEGF TherapyJ Ophthalmol201720171410.1155/2017/5632634


© This is an open access article distributed under the terms of the Creative Commons Attribution License - Attribution 4.0 International (CC BY 4.0). which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Article type

Original Article

Article page


Authors Details

Anand Babu M N, Prashanth C N, Sribhargava Natesh

Article History

Received : 06-09-2020

Accepted : 29-09-2020

Available online : 02-04-2021

Article Metrics

View Article As


Downlaod Files